Source:European Journal of Cancer, Volume 78
Author(s): René Adam, Bin Yi, Pasquale F. Innominato, Eduardo Barroso, Christophe Laurent, Felice Giuliante, Lorenzo Capussotti, Réal Lapointe, Jean-Marc Regimbeau, Santiago Lopez-Ben, Helena Isoniemi, Catherine Hubert, Jen-Kou Lin, Thomas Gruenberger, Dominique Elias, Oleg G. Skipenko, Alfredo Guglielmi
PurposePatient outcome after resection of colorectal liver metastases (CLM) following second-line preoperative chemotherapy (PCT) performed for insufficient response or toxicity of the first-line, is little known and has here been compared to the outcome following first-line.Patients and methodsFrom January 2005 to June 2013, 5624 and 791 consecutive patients of a prospective international cohort received 1 and 2 PCT lines before CLM resection (group 1 and 2, respectively). Survival and prognostic factors were analysed.ResultsAfter a mean follow-up of 30.1 months, there was no difference in survival from CLM diagnosis (median, 3-, and 5-year overall survival [OS]: 58.6 months, 76% and 49% in group 2 versus 58.9 months, 71% and 49% in group 1, respectively, P = 0.32). After hepatectomy, disease-free survival (DFS) was however shorter in group 2: 17.2 months, 27% and 15% versus 19.4 months, 32% and 23%, respectively (P = 0.001). Among the initially unresectable patients of group 1 and 2, no statistical difference in OS or DFS was observed. Independent predictors of worse OS in group 2 were positive primary lymph nodes, extrahepatic disease, tumour progression on second line, R2 resection and number of hepatectomies/year <50. Positive primary nodes, synchronous and bilateral metastases were predictors of shorter DFS. Initial unresectability did not impact OS or DFS in group 2.ConclusionCLM resection following second-line PCT, after oncosurgically favourable selection, could bring similar OS compared to what observed after first-line. For initially unresectable patients, OS or DFS is comparable between first- and second-line PCT. Surgery should not be denied after the failure of first-line chemotherapy.
http://ift.tt/2oSlyUg
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου